Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Targeting CD22 as a strategy for treating systemic autoimmune diseases

Authors Thomas Dörner, David M Goldenberg

Published 15 November 2007 Volume 2007:3(5) Pages 953—959

Thomas Dörner1, David M Goldenberg2

1Charite University Hospital Berlin and Deutsche Rheumaforschungszentrum, Berlin, Germany; 2Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA

Abstract: B-cells play an important role in the diagnosis and to some extent the pathogenesis of many autoimmune diseases. Specific B-cell directed antibodies are now gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of rituximab in the management of B-cell malignancies as well as rheumatoid arthritis. A second candidate target is CD22, and the first antagonistic antibody to this B-cell marker is epratuzumab, which appears to function, in contrast to CD20 antibodies, more by modulation of B-cells than by their depletion capacity. Originally developed for the treatment of non-Hodgkin lymphoma, epratuzumab has now been reported to be effective, with a very good safety profile, in two prototype autoimmune diseases, systemic lupus erythematosus and primary Sjögren’s syndrome. As such, this new investigational antibody may provide distinct therapeutic effects and may be complementary to the known effects and role of CD20 antibodies.

Keywords: autoimmune diseases, CD22, B-cells, epratuzumab

Download Article [PDF] 

Readers of this article also read:

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Anand N, Sehgal R, Kanwar RK, Dubey ML, Vasishta RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:6355-6369

Published Date: 8 October 2015

Preliminary findings on the reliability and validity of the Cantonese Birmingham Cognitive Screen in patients with acute ischemic stroke

Pan X, Chen H, Bickerton WL, Lau JKL, Kong APH, Rotshtein P, Guo A, Hu J, Humphreys GW

Neuropsychiatric Disease and Treatment 2015, 11:2377-2390

Published Date: 16 September 2015

A regenerative label-free fiber optic sensor using surface plasmon resonance for clinical diagnosis of fibrinogen

Nguyen TT, Bea SO, Kim DM, Yoon WJ, Park J-W, An SSA, Ju H

International Journal of Nanomedicine 2015, 10:155-163

Published Date: 27 August 2015

To what extent is clinical and laboratory information used to perform medication reviews in the nursing home setting? the CLEAR study

Mestres Gonzalvo C, Hurkens KPGM, de Wit HAJM, van Oijen BPC, Janknegt R, Schols JMGA, Mulder WJ, Verhey FR, Winkens B, van der Kuy PHM

Therapeutics and Clinical Risk Management 2015, 11:767-777

Published Date: 8 May 2015

Postural stability and quality of life after guided and self-training among older adults residing in an institutional setting

Tuunainen E, Rasku J, Jäntti P, Moisio-Vilenius P, Mäkinen E, Toppila E, Pyykkö I

Clinical Interventions in Aging 2013, 8:1237-1246

Published Date: 16 September 2013

Editorial - Clinical Epidemiology

Henrik Toft Sørensen

Clinical Epidemiology 2009, 1:17-18

Published Date: 27 February 2009

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007